Program
mRNA COVID-19 Vaccine
Also written as “COVID-19 mRNA vaccine”, “COVID-19 mRNA Vaccine (ZSVG-02-O)” and “COVID-19 mRNA Vaccine (nucleoside modified)”.
Its studies are mostly in COVID-19 · Respiratory Syncytial Virus Infections · Influenza, Human · Severe Acute Respiratory Syndrome, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CanSino Biologics | 20 open or running | phase 2since May 12, 2022 | May 12, 2022 | none ahead |
| CNBG-Virogin Biotech (Shanghai) | 22 open or running | phase 2since Oct 31, 2023 | Oct 31, 2023 | none ahead |
| Sanofi | 20 open or running | phase 2since Mar 11, 2021 | Mar 11, 2021 | none ahead |
| Argorna Pharmaceuticals | 10 open or running | phase 1since May 28, 2023 | May 28, 2023 | none ahead |
| Bayer | 10 open or running | phase 3since Apr 16, 2021 | Apr 16, 2021 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 3since Apr 16, 2024 | Apr 16, 2024 | none ahead |
| Invivyd | 10 open or running | phase 3since Jun 8, 2026 | Jun 8, 2026 | none ahead |
| Stemirna Therapeutics | 10 open or running | phase 2since Nov 11, 2021 | Nov 11, 2021 | none ahead |
| Vaccine | 10 open or running | phase 1since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| Walvax Biotechnology | 10 open or running | phase 3since Apr 13, 2021 | Apr 13, 2021 | none ahead |
Also a collaborator on its studies: Abogen Biosciences and BioNTech.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2021First study: phase 2 study in COVID-19New to SanofiSanofi · NCT04798027 · 182 enrolled · United States, Australia, Brazil and more
- Apr 13, 2021Walvax Biotechnology’s first study: phase 3 study in COVID-19New to Walvax BiotechnologyWalvax Biotechnology · NCT04847102 · 28,000 enrolled · Indonesia, Mexico
- Apr 16, 2021Bayer’s first study: phase 3 study in COVID-19New to BayerBayer · NCT04848467
- Jul 16, 2021Phase 2 study in Influenza, HumanSanofi · NCT04969276 · 306 enrolled · United States
- Nov 11, 2021Stemirna Therapeutics’ first study: phase 2 study in COVID-19New to Stemirna TherapeuticsStemirna Therapeutics · NCT05144139 · 480 enrolled · Lao People's Democratic Republic
- May 12, 2022CanSino Biologics’ first study: phase 1 study in COVID-19New to CanSino BiologicsCanSino Biologics · NCT05373485 · 43 enrolled · China
- May 12, 2022Phase 2 study in COVID-19CanSino Biologics · NCT05373472 · 150 enrolled · China
- May 28, 2023Argorna Pharmaceuticals’ first study: phase 1 study in SARS-CoV-2New to Argorna PharmaceuticalsArgorna Pharmaceuticals · NCT05897190 · 60 enrolled · China
- Jul 5, 2023Vaccine’s first study: phase 1 study in Severe Acute Respiratory SyndromeNew to VaccineVaccine · NCT05938075 · 130 enrolled · South Africa
- Oct 31, 2023CNBG-Virogin Biotech (Shanghai)’s first study: phase 1 study in COVID-19New to CNBG-Virogin Biotech (Shanghai)CNBG-Virogin Biotech (Shanghai) · NCT06113744 · 164 planned · China
- Oct 31, 2023Phase 2 study in COVID-19CNBG-Virogin Biotech (Shanghai) · NCT06113731 · 980 planned · China
- Apr 16, 2024GlaxoSmithKline’s first study: phase 3 study in Respiratory Syncytial Virus InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT06374394 · 841 enrolled · United States, Belgium, Netherlands and more
- Jun 8, 2026Invivyd’s first study: phase 3 study in COVID-19New to InvivydInvivyd · NCT07655180 · 210 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“mRNA COVID-19 Vaccine”name, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07655180COVID-19 · United States | 3 | Completed | Invivyd | Aug 15, 2026 | 210 |
| NCT06374394Respiratory Syncytial Virus Infections · United States, Belgium, Netherlands and more | 3 | Completed | GlaxoSmithKline | Nov 1, 2024 | 841 |
| NCT06113744COVID-19 · China | 1 | Recruiting | CNBG-Virogin Biotech (Shanghai) | Jun 30, 2023 | 164 |
| NCT06113731COVID-19 · China | 2 | Recruiting | CNBG-Virogin Biotech (Shanghai) | Oct 30, 2023 | 980 |
| NCT05938075Severe Acute Respiratory Syndrome · South Africa | 1 | Completed | Vaccine | Jul 25, 2024 | 130 |
| NCT05897190SARS-CoV-2 · China | 1 | Completed | Argorna Pharmaceuticals | Jun 13, 2022 | 60 |
| NCT05373485COVID-19 · China | 1 | Completed | CanSino Biologics | Aug 8, 2022 | 43 |
| NCT05373472COVID-19 · China | 2 | Completed | CanSino Biologics | Sep 21, 2022 | 150 |
| NCT05144139COVID-19 · Lao People's Democratic Republic | 2 | Completed | Stemirna Therapeutics | Aug 28, 2022 | 480 |
| NCT04969276Influenza, Human · United States | 2 | Completed | Sanofi | Feb 8, 2022 | 306 |
| NCT04848467COVID-19 | 3 | Withdrawn | Bayer | Nov 30, 2021 | 0 |
| NCT04847102COVID-19 · Indonesia, Mexico | 3 | UNKNOWN | Walvax Biotechnology | Nov 30, 2021 | 28,000 |
| NCT04798027COVID-19 · United States, Australia, Brazil and more | 2 | Terminated | Sanofi | Jun 27, 2022 | 182 |
How it is read
Names in the registry
- “COVID-19 mRNA vaccine”, 6 entries
- “COVID-19 mRNA Vaccine (ZSVG-02-O)”, 2 entries
- “COVID-19 mRNA Vaccine (nucleoside modified)”, 1 entry
- “SARS-CoV-2 mRNA vaccine formulation 1”, 1 entry
- “SARS-CoV-2 mRNA vaccine formulation 2”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 9 studies
- Respiratory Syncytial Virus Infections, 1 study
- Influenza, Human, 1 study
- Severe Acute Respiratory Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.